RxDoctor Payments DataLook up a doctor →

Benjamin Dehner, MD

Urology · Nashville, TNNPI 1649481938

Payments from drug & device makers

$164,922in general payments, 2019–2025

Across 614 payments — averaging $268.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$153K
  • Intuitive Surgical$3K
  • Axonics, Inc.$2K
  • Pfizer$882
  • Astellas Pharma US Inc$607
  • Sumitomo Pharma America, Inc.$597
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$14,3549%
  • Speaking & faculty fees$130,00879%
  • Travel & lodging$6,7414%
  • Food & beverage$12,3708%
  • Education$1,4491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$164,922 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$946,735
Medicare patients
812
Services billed
13,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide136$1,881,526
OrgovyxRelugolix93$250,439
MyrbetriqMirabegron158$133,655
GemtesaVibegron129$123,204
FirmagonDegarelix Acetate128$65,980
Alfuzosin Hcl ErAlfuzosin Hcl605$14,251
Cefdinir979$10,850
Desmopressin Acetate171$8,195
Tamsulosin Hcl553$7,849
Potassium Citrate ErPotassium Citrate59$6,819
Testosterone Cypionate103$4,374
Testosterone25$4,199
Tolterodine Tartrate ErTolterodine Tartrate21$3,115
Sildenafil Citrate22$1,437
Finasteride74$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$607$2,015,181294 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$597$373,643222 claims
Ferring Pharmaceuticals Inc.Firmagon$149$65,980128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.

Other urology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →